MX2013005994A - Monobactamas. - Google Patents

Monobactamas.

Info

Publication number
MX2013005994A
MX2013005994A MX2013005994A MX2013005994A MX2013005994A MX 2013005994 A MX2013005994 A MX 2013005994A MX 2013005994 A MX2013005994 A MX 2013005994A MX 2013005994 A MX2013005994 A MX 2013005994A MX 2013005994 A MX2013005994 A MX 2013005994A
Authority
MX
Mexico
Prior art keywords
monobactams
directed
present
bacterial infections
new class
Prior art date
Application number
MX2013005994A
Other languages
English (en)
Spanish (es)
Inventor
Matthew Frank Brown
Mark Stephen Plummer
Veerabahu Shanmugasundaram
Hud Lawrence Risley
Mark J Mitton-Fry
Seungil Han
Manjinder Lall
Jeremy T Starr
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2013005994A publication Critical patent/MX2013005994A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2013005994A 2010-11-29 2011-11-15 Monobactamas. MX2013005994A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41757510P 2010-11-29 2010-11-29
PCT/IB2011/055104 WO2012073138A1 (en) 2010-11-29 2011-11-15 Monobactams

Publications (1)

Publication Number Publication Date
MX2013005994A true MX2013005994A (es) 2013-07-15

Family

ID=45315854

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005994A MX2013005994A (es) 2010-11-29 2011-11-15 Monobactamas.

Country Status (17)

Country Link
US (3) US20120302542A1 (enExample)
EP (1) EP2646436B1 (enExample)
JP (1) JP5777725B2 (enExample)
KR (1) KR101514587B1 (enExample)
CN (1) CN103228652B (enExample)
AR (1) AR084001A1 (enExample)
AU (1) AU2011336209B2 (enExample)
CA (1) CA2815821C (enExample)
DK (1) DK2646436T3 (enExample)
ES (1) ES2542431T3 (enExample)
IL (1) IL226052A0 (enExample)
MX (1) MX2013005994A (enExample)
SG (1) SG190007A1 (enExample)
TW (1) TW201247661A (enExample)
UY (1) UY33754A (enExample)
WO (1) WO2012073138A1 (enExample)
ZA (1) ZA201304479B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9988373B2 (en) 2013-12-26 2018-06-05 Shionogi & Co., Ltd. Nitrogen-containing six-membered cyclic derivatives and pharmaceutical composition comprising the same
HUE042134T2 (hu) * 2014-03-24 2019-06-28 Novartis Ag Monobaktám szerves vegyületek bakteriális fertõzések kezelésére
AU2016327264B2 (en) 2015-09-23 2019-06-27 Novartis Ag Salts and solid forms of monobactam antibiotic
CN105481812B (zh) * 2015-11-30 2020-04-21 重庆天奕恒化科技有限公司 一种5-苄氧基-4-氧代-4h-吡喃-2-羧酸的制备方法
AU2016371600B2 (en) 2015-12-15 2021-02-18 Merck Sharp & Dohme Llc Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections
US10407421B2 (en) 2016-03-07 2019-09-10 Merck Sharp & Dohme Corp Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
CN107641119B (zh) 2016-07-21 2019-11-08 中国科学院上海药物研究所 单环β-内酰胺-铁载体轭合物及其制备方法和用途
ES2912656T3 (es) 2017-08-02 2022-05-26 Novartis Ag Proceso para preparar ácido 1-(((Z)-(1-(2-aminotiazol-4-il)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-il)metil)-1-sulfoacetidin-3-il)amino)etiliden)amino)oxi)ciclopropano carboxílico
GEAP202215303A (en) 2017-10-02 2022-04-11 Merck Sharp & Dohme Chromane monobactam compounds for the treatment of bacterial infections
US10513504B2 (en) 2018-03-08 2019-12-24 Apotex Inc. Processes for the preparation of apalutamide and intermediates thereof
KR102786898B1 (ko) * 2019-11-22 2025-03-25 쑤저우 얼예 파마슈티칼 컴퍼니 리미티드 설포닐우레아 고리 치환 모노시클릭 β-락탐계 항생제
PH12022551379A1 (en) 2019-12-06 2023-05-03 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
CN111303144B (zh) * 2019-12-13 2020-11-27 苏州信诺维医药科技有限公司 一种治疗细菌感染的化合物
US12528804B2 (en) 2021-03-31 2026-01-20 Fedora Pharmaceuticals Inc. Lactivicin compounds, their preparation and use as antibacterial agents
US11780832B2 (en) 2021-03-31 2023-10-10 Fedora Pharmaceuticals Inc. Lactivicin compounds, their preparation and use as antibacterial agents
KR102781293B1 (ko) * 2021-05-07 2025-03-17 한국생명공학연구원 신규 사이드로포어 화합물 및 이를 이용한 금속 나노입자 복합체
SI4347031T1 (sl) 2021-06-04 2026-01-30 Vertex Pharmaceuticals Incorporated N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov
CR20240212A (es) 2021-11-18 2024-07-01 Merck Sharp & Dohme Llc Compuestos monobactámicos de cromano amidina para tratar las infecciones bacterianas
JP7671398B2 (ja) * 2021-11-18 2025-05-01 メルク・シャープ・アンド・ドーム・エルエルシー クロマンアミジンモノバクタム抗生物質
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
CN115304594B (zh) * 2022-10-12 2023-02-14 苏州二叶制药有限公司 磺酰脲环取代的化合物的盐型及其晶型
WO2026043829A1 (en) * 2024-08-21 2026-02-26 Merck Sharp & Dohme Llc Chromane cyclic amidine monobactam compounds for the treatment of bacterial infections

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01502660A (ja) * 1986-05-23 1989-09-14 ジ・アップジョン・カンパニー N―1置換スルホニルアミノカルボニル、c―4置換モノバクタム類
KR101403164B1 (ko) 2005-12-07 2014-06-03 바실리어 파마슈티카 아게 베타-락타마아제 저해제 및 모노박탐 항생물질의 유용한조합
WO2008116301A1 (en) 2007-03-28 2008-10-02 Apotex Technologies Inc. Fluorinated derivatives of deferiprone
CA2744756C (en) * 2008-12-19 2013-05-28 Pfizer Inc. Monocarbams and their use as antibacterial agent

Also Published As

Publication number Publication date
AR084001A1 (es) 2013-04-17
DK2646436T3 (en) 2015-06-29
US20150148326A1 (en) 2015-05-28
ZA201304479B (en) 2014-03-26
EP2646436A1 (en) 2013-10-09
AU2011336209A1 (en) 2013-05-30
UY33754A (es) 2012-06-29
JP5777725B2 (ja) 2015-09-09
CA2815821A1 (en) 2012-06-07
JP2013544276A (ja) 2013-12-12
KR101514587B1 (ko) 2015-04-22
KR20130112054A (ko) 2013-10-11
IL226052A0 (en) 2013-06-27
CN103228652B (zh) 2015-02-18
CA2815821C (en) 2015-07-07
HK1184462A1 (en) 2014-01-24
TW201247661A (en) 2012-12-01
US20130252935A1 (en) 2013-09-26
AU2011336209B2 (en) 2015-03-19
WO2012073138A1 (en) 2012-06-07
EP2646436B1 (en) 2015-05-27
CN103228652A (zh) 2013-07-31
ES2542431T3 (es) 2015-08-05
US20120302542A1 (en) 2012-11-29
SG190007A1 (en) 2013-06-28

Similar Documents

Publication Publication Date Title
IN2012DN00692A (enExample)
MX2012001618A (es) Derivados de 5-fluoropirimidinona.
PH12012502138B1 (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives
PH12013501780A1 (en) Fluoro-pyridinone derivatives useful as antibacterial agents
MX2013011526A (es) Derivados de isoxazol utiles como agentes antibacteriales .
MX351464B (es) El uso de un agonista del receptor 8 tipo toll para el tratamiento de enfermedades alérgicas.
JO3131B1 (ar) مركبات كيميائية
HUE059033T2 (hu) Benzoxaborol-származékok bakteriális fertõzések kezelésére
UY33754A (es) Monobactamas
HRP20180972T1 (hr) Kombinacija fenoksibenzamina i polimiksina e za liječenje mikrobnih infekcija
EP2831069A4 (en) ISOXAZOL-beta-lactamase INHIBITORS
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
MX385616B (es) Inhibidores de cdk
IN2012DN00539A (enExample)
PL3443957T3 (pl) Związki i kompozycje stosowane w leczeniu nowotworów
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
IN2012DN00695A (enExample)
UA114417C2 (uk) Інгібітори iap
EA201291329A1 (ru) Гетероциклические соединения, их получение и их терапевтическое применение
HRP20190169T1 (hr) Postupci liječenja povećanja tjelesne težine inducirane antipsihoticima
EA201270728A1 (ru) Пуриновые соединения
MX2013005825A (es) Benzoxazepinas como inhibidores de objetivo de rapamicina en mamiferos (mtor) y metodos de uso y fabricacion.
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.

Legal Events

Date Code Title Description
FG Grant or registration